Helix Acquisition Corp. III, Backed by Cormorant, Raises $150M in IPO

Why It Matters

The capital infusion expands financing options for late‑stage biotech startups, while Cormorant’s track record signals renewed investor confidence in SPACs as a viable path to liquidity.

Key Takeaways

• Helix III raised $150M, selling 15M shares.
• Cormorant now launched three biotech SPACs since 2022.
• SPAC issuances doubled from 2024 to 2025.
• No merger target yet; focus on healthcare sector.
• Backlog of mature biotech firms ripe for SPAC deals.

Pulse Analysis

The resurgence of special‑purpose acquisition companies in 2025 has reshaped how biotech firms access public capital. After a steep decline post‑2020, SPACs have more than doubled in issuance year‑over‑year, driven by seasoned sponsors like Cormorant Asset Management. Helix Acquisition Corp. III’s $150 million IPO underscores investors’ appetite for vehicles that can bridge the funding gap left by a sluggish traditional IPO market, especially for companies developing high‑cost therapeutics.

Cormorant’s strategy leverages its deep portfolio of over 50 biotech investments, many of which have already navigated successful public listings or exits. The firm’s previous SPAC mergers—Moonlake Immunotherapeutics and BridgeBio Oncology—demonstrated that a well‑executed blank‑check deal can accelerate product commercialization and create shareholder value even in a challenging funding climate. By positioning Helix III to target healthcare‑related businesses, Cormorant taps into a backlog of mature, private biotech firms that have delayed IPOs due to market volatility, offering them a faster, less dilutive route to liquidity.

Looking ahead, Helix III’s lack of a disclosed target suggests a pipeline of potential candidates ranging from gene‑editing platforms to niche oncology assets. As capital markets continue to favor alternative financing structures, investors will watch Cormorant’s next move closely, expecting that a successful merger could reinforce confidence in SPACs and stimulate further capital inflows into the biotech sector. This dynamic could reshape funding strategies, prompting more private innovators to consider SPACs as a primary path to scale their pipelines and deliver breakthroughs to patients faster.

Deal Summary

Biotech investor Cormorant Asset Management launched Helix Acquisition Corp. III, a SPAC that raised $150 million in its initial public offering on the Nasdaq. The SPAC, which currently has no merger target, aims to focus on healthcare and related industries. The IPO was announced on Jan. 26, 2026.